<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37657668</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>218</Volume><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>CUR-N399, a PI4KB inhibitor, for the treatment of Enterovirus A71 infection.</ArticleTitle><Pagination><StartPage>105713</StartPage><MedlinePgn>105713</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2023.105713</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(23)00191-2</ELocationID><Abstract><AbstractText>Over the years, the hand, foot and mouth disease (HFMD) has sparked epidemics across many countries which mainly affected young children. While symptoms are usually mild, severe complications may arise, and some even lead to death. Such concerns, coupled with the lack of approved vaccines and antivirals to date, create an urgency in the identification of safe therapeutics against HFMD. The disease is mainly transmitted by enteroviruses like enterovirus A71 (EV-A71). Essential for enterovirus replication is the host protein, PI4KB. In this study, we investigate the antiviral efficacy of a novel PI4KB inhibitor, CUR-N399. We found that CUR-N399 displayed broad-spectrum antiviral activity against picornaviruses in cell culture models. Using a suckling mouse model of lethal EV-A71 infection, CUR-N399 was found to be well-tolerated, promote survival and reduce viral titre in mice organs. Together, these support the discovery of CUR-N399 as an antiviral against EV-A71 and potentially other closely related viruses.</AbstractText><CopyrightInformation>Copyright Â© 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheong</LastName><ForeName>Dorothy Hui Juan</ForeName><Initials>DHJ</Initials><AffiliationInfo><Affiliation>Infectious Disease Translational Research Programme and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yogarajah</LastName><ForeName>Thinesshwary</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infectious Disease Translational Research Programme and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Yi Hao</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbrandt</LastName><ForeName>Gustav</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Curovir AB, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westman</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Curovir AB, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin Jang Hann</ForeName><Initials>JJH</Initials><AffiliationInfo><Affiliation>Infectious Disease Translational Research Programme and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Collaborative and Translation Unit for Hand, Foot and Mouth Disease (HFMD), Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore. Electronic address: miccjh@nus.edu.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">CUR-N399</Keyword><Keyword MajorTopicYN="N">Enterovirus A71</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">PI4KB inhibitor</Keyword></KeywordList><CoiStatement>Declaration of competing interest CUR-N399 is covered in patent/patent applications owned by Curovir AB (J.W. and G.A.). D.H.J.C., T.Y., Y.H.W and J.J.H.C. declare no potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>2</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>2</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37657668</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2023.105713</ArticleId><ArticleId IdType="pii">S0166-3542(23)00191-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>